#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	18180	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2106	858.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1435	1435	C	1070	C,T	1016,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33030	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3432	957.6	0	.	n	.	0	T695C	SNP	695	695	T	966	966	C	1012	C	964	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33030	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3432	957.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1608	1608	A	1083	A	1020	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33030	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3432	957.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2242	2242	C	1085	C	1009	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33030	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3432	957.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2316	2316	A	1080	A	1030	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33030	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3432	957.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2868	2868	C	1015	C	954	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2382	folP	852	852	100.0	folP.l15.c4.ctg.1	1569	151.3	1	SNP	p	R228S	1	.	.	682	684	AGC	986	988	AGC	259;261;260	A;G,A;C	245;247,1;246	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5806	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3334	173.7	1	SNP	p	S91F	0	.	.	271	273	TCC	622	624	TCC	178;179;182	T,C;C;C	166,1;173;171	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5806	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3334	173.7	1	SNP	p	D95N	0	.	.	283	285	GAC	634	636	GAC	179;178;176	G;A;C	174;174;171	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5806	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3334	173.7	1	SNP	p	D95G	0	.	.	283	285	GAC	634	636	GAC	179;178;176	G;A;C	174;174;171	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1298	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1217	106.5	0	.	p	.	0	D79N	NONSYN	235	237	GAT	526	528	AAT	184;185;185	A;A;T	167;169;167	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1298	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1217	106.5	0	.	p	.	0	A86T	NONSYN	256	258	GCG	547	549	ACG	188;185;186	A;C,T;G	172;168,1;169	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1298	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1217	106.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	604	606	CAC	188;188;188	C;A;C	175;171;177	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1298	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1217	106.5	0	.	p	.	0	S183N	NONSYN	547	549	AGT	838	840	AAT	73;70;70	A;A,G;T,G	71;68,1;68,1	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1298	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1217	106.5	0	.	p	.	0	M197I	NONSYN	589	591	ATG	880	882	ATA	60;63;65	A;T;A,G	60;63;64,1	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1298	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1217	106.5	1	SNP	p	G45D	0	.	.	133	135	GGC	424	426	GGC	197;198;195	G;G,A;C	185;185,1;183	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6212	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2908	212.6	1	SNP	p	D86N	0	.	.	256	258	GAC	608	610	GAC	252;250;252	G;A;C	235;231;236	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6212	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2908	212.6	1	SNP	p	S87R	0	.	.	259	261	AGT	611	613	AGT	253;255;254	A;G;T	234;238;235	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6212	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2908	212.6	1	SNP	p	S87I	0	.	.	259	261	AGT	611	613	AGT	253;255;254	A;G;T	234;238;235	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6212	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2908	212.6	1	SNP	p	S87W	0	.	.	259	261	AGT	611	613	AGT	253;255;254	A;G;T	234;238;235	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6212	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2908	212.6	1	SNP	p	S88P	0	.	.	262	264	TCC	614	616	TCC	255;259;258	T;C;C,A	236;241;239,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5062	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2661	189.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1527	1529	GGC	252;247;248	G;G;C	238;233;229	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1277	1279	GCA	265;269;269	G;C;A	246;250;253	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1280	1282	ATC	272;268;270	A;T;C	254;252;252	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1292	1294	GTG	276;275;273	G,C;T;G	256,1;256;253	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1292	1294	GTG	276;275;273	G,C;T;G	256,1;256;253	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1796	1798	ACC	247;247;248	A;C;C	230;233;234	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1850	1852	GCG	247;247;243	G;C;G	218;196;201	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1850	1852	GCG	247;247;243	G;C;G	218;196;201	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1973	1975	GGC	175;174;175	G;G;C	162;162;167	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1982	1984	GGC	173;172;174	G;G;C	158;155;162	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4742	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2468	191.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2000	2002	CCG	144;145;141	C,G;C,G;G	103,5;102,1;104	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6876	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2991	229.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1522	1524	CTG	267;262;263	C,A;T;G,T	239,1;234;237,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2622	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1643	158.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	506	506	C	185	C	166	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	A251V	NONSYN	751	753	GCG	60	62	GTA	47;46;46	G;T;A	41;41;41	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	S271T	NONSYN	811	813	TCG	120	122	ACT	80;77;76	A;C;T	67;66;65	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	126	128	GAT	65;60;57	G;A;T	58;55;54	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	D276N	NONSYN	826	828	GAT	135	137	AAC	58;59;60	A;A;C	56;56;57	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	N277H	NONSYN	829	831	AAC	138	140	CAC	60;60;60	C;A;C	56;56;57	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	R307E	NONSYN	919	921	AGA	228	230	GAA	20;20;20	G;A;A	20;20;20	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	240	242	GCA	17;17;16	G;C;A	17;17;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	243	245	GAC	16;16;16	G;A;C	15;16;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	249	251	ATC	16;16;16	A;T;C	16;16;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	255	257	TCG	18;17;17	T;C;G	18;16;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	261	263	GCC	18;18;18	G;C;C	17;18;18	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	264	266	AGC	18;18;18	A;G;C	17;17;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	267	269	GCC	18;18;18	G;C;C	16;17;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	380	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	442	30.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	273	275	GTT	16;16;16	G,T;T;T	14,1;16;15	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	0	.	p	.	0	I45V	NONSYN	133	135	ATT	382	384	GTT	285;284;285	G;T;T	269;264;269	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	0	.	p	.	0	I75V	NONSYN	223	225	ATT	472	474	GTT	277;281;287	G;T;T	253;249;256	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	0	.	p	.	0	S89T	NONSYN	265	267	AGC	514	516	ACC	295;296;291	A;C;C	253;267;268	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	0	.	p	.	0	I98V	NONSYN	292	294	ATC	541	543	GTC	290;285;284	G;T;C	270;261;267	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	1	SNP	p	G120K	1	.	.	358	360	AAG	607	609	AAG	275;276;281	A;A;G	264;264;265	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	1	SNP	p	N121D	0	.	.	361	363	AAC	610	612	AAC	281;274;278	A;A;C,A	267;259;264,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3626	porB1b	1038	1038	99.52	porB1b.l6.c4.ctg.1	1498	240.7	1	SNP	p	A121N	1	.	.	361	363	AAC	610	612	AAC	281;274;278	A;A;C,A	267;259;264,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	13164	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5002	262.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1988	1990	AAT	275;279;276	A;A;T	263;267;265	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1456	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	986	147.3	1	SNP	p	V57M	1	.	.	169	171	ATG	455	457	ATG	311;312;310	A;T;G	300;301;297	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
